Good news for Stemson, this company that is developing a technology to automate and scale the generation of iPS cells just announced a relatively big seed round ($16 million) to develop their tech. Basically, this tech would make the Stemson treatment more cheaper, reliable, and faster.
Massachusetts-based biotech announces closing of $16m seed round for stem cell therapy led by The Engine and Khosla Ventures.
www.longevity.technology
Induced Pluripotent Stem Cells (iPSCs) are derived from skin or blood cells that have been reprogrammed so they revert to an embryonic-like pluripotent state; pluripotency enables the cell to develop into any type of human cell, meaning they are fantastic for therapeutic purposes. iPSCs can be triggered to become beta islet cells for diabetes treatment, or neurons for neurological treatment or blood cells, in order to generate new cancer-free blood for leukaemia sufferers.
However, scientists usually have to go through the labour-intensive process of inspecting iPSCs in order to manually weed out ones deemed to be of lower quality. Cellino’s platform could be set to change all that.
Cellino is developing an automated process to generate autologous iPSCs at scale, using machine-learning algorithms to train software to identify both low- and high-quality cells. The software then controls a laser to destroy the unwanted cells. The proprietary platform converges breakthrough technologies across optics, biology and machine learning to engineer high functionality cells with high levels of consistency and yield.
Cellino plans to use this seed financing to scale up this technology, automating and standardising autologous stem cell production, and thereby accelerating the development of life-saving and life-extending therapies for patients.